IMRA News and Press, IMARA Inc. From 07/13/21

Imara (IMRA) announces that it has commenced a proposed underwritten public offering of $50M of shares.Intends to grant the underwriters a 30-day option to purchase up to an additional $7.5M of shares.Shares down 11% post market. For further details see: Imara shares slide on $50M ...

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today...

BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the election of Lau...

The following slide deck was published by IMARA Inc. in conjunction with this event. For further details see: IMARA (IMRA) EHA Investor Presentations - Slideshow

BOSTON, June 17, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the grant recipient...

Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial data through eight months show increased HbF response and continuation of lower VOC r...

Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at 8:00 a.m. ET BOSTON, June 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq:...

Imara, Inc. (IMRA) Q1 2021 Earnings Conference Call April 11, 2021 08:30 ET Company Participants Michael Gray - Chief Financial Officer & Chief Operating Officer Rahul Ballal - President, Chief Executive Officer & Director Conference Call Participants Yigal Nochomovitz - Citigroup Mat...

Imara (IMRA): Q1 GAAP EPS of -$0.58 beats by $0.25.Cash, cash equivalents and investments were $75.6 million as of March 31, 2021.Press Release For further details see: Imara EPS beats by $0.25

On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the transfusion-dependent beta-thalassemia arm of the Forte Phase 2b trial Higher dose arms open...